Brawn Biotech

Which are the latest news on Brawn Biotech?

Why is Brawn Biotech Ltd falling/rising?

As of 10-Jun, Brawn Biotech Ltd's stock price is 20.05, unchanged from the previous session, but has declined 4.75% over the past week and 6.79% year-to-date, underperforming the Sensex. The stock is currently in a bearish trend with significant losses and reduced investor participation.

As of 10-Jun, Brawn Biotech Ltd's stock price is currently at 20.05, showing no change from the previous trading session. The stock has experienced a decline of 4.75% over the past week, underperforming the benchmark Sensex, which fell only 0.49% during the same period. Over the last month, the stock has decreased by 2.20%, while the Sensex has dropped by 4.33%. Year-to-date, Brawn Biotech's stock is down 6.79%, contrasting with the Sensex's decline of 13.19%. However, the stock has shown a positive performance over the past year, increasing by 23.38%, while the Sensex has decreased by 10.21%.<BR><BR>Today's trading performance indicates that Brawn Biotech has underperformed its sector by 6.34%. The stock opened with a significant loss of 4.99% and reached an intraday low of Rs 20. Additionally, the stock has been trading in a narrow range of Rs 0.06 and is currently below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. Furthermore, there has been a notable decline in investor participation, with delivery volume dropping by 74.39% compared to the 5-day average. This combination of factors contributes to the stock's current downward trajectory.

What does Brawn Biotech do?

Brawn Biotech Ltd is a healthcare group in the Pharmaceuticals & Biotechnology sector, reporting net sales of 2 Cr and a net profit of 1 Cr for the quarter ending March 2026, with a market cap of INR 6 Cr. The company has a P/E ratio of 6.00 and a return on equity of 25.41%.

Overview:<BR>Brawn Biotech Ltd is a fully integrated healthcare group operating in the Pharmaceuticals & Biotechnology industry within the Micro Cap market-cap bracket.<BR><BR>History:<BR>Brawn Biotech Ltd was originally incorporated as Brawn Pharmaceuticals Limited in November 1985. The company changed its name to Brawn Biotech Limited in November 2010. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Mar 2026)<BR>- Market-cap: INR 6 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 6.00<BR>- Industry P/E: 27<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.05<BR>- Return on Equity: 25.41%<BR>- Price to Book: 1.71<BR><BR>Contact Details:<BR>Address: C-64 Lajpat Nagar-1 1st Floor, New Delhi, New Delhi: 110024<BR>Email: solution@brawnpharma.com<BR>Website: http://www.brawnbiotech.com

Should I buy, sell or hold Brawn Biotech Ltd?

Are Brawn Biotech Ltd latest results good or bad?

Brawn Biotech Ltd's latest results are concerning, showing a net loss of ₹0.04 crores in Q2 FY26, a 117.39% decline in profitability from the previous quarter, stagnant revenue, and deteriorating operating margins, indicating significant operational challenges and a troubling financial outlook.

Brawn Biotech Ltd's latest results indicate a troubling financial situation. In Q2 FY26, the company reported a net loss of ₹0.04 crores, a significant decline from a profit of ₹0.23 crores in the previous quarter, marking a dramatic 117.39% drop in profitability. Revenue remained stagnant at ₹0.12 crores, unchanged from the prior quarter, highlighting severe challenges in business momentum.<BR><BR>The operating margin has also deteriorated sharply, falling to -33.33% from a positive 25.0% in Q1 FY26. This indicates significant operational inefficiencies and cost pressures that the company has been unable to manage effectively. Additionally, the return on equity stands at a concerning -16.49%, reflecting the company's struggle to generate positive returns for shareholders.<BR><BR>Over the past five years, Brawn Biotech has seen its annual revenues plummet by 73.47%, raising fundamental concerns about the viability of its business model. The company's financial trajectory is characterized by persistent losses, minimal revenue growth, and a lack of institutional interest, which further complicates its outlook.<BR><BR>In summary, the latest results are indicative of a deteriorating financial condition, with multiple red flags suggesting that the company is facing significant operational and structural challenges.

When is the next results date for Brawn Biotech Ltd?

The next results date for Brawn Biotech Ltd is 29 May 2026.

The next results date for Brawn Biotech Ltd is scheduled for 29 May 2026.

How has been the historical performance of Brawn Biotech?

As of March 2023, Brawn Biotech reported net sales and total operating income of 0.48 crore, with a profit after tax of 0.19 crore and a PAT margin of 39.58%. The company has total assets and liabilities of 14.37 crore each, no debt, and stagnant cash flow, indicating limited operational activity and a need for revenue growth.

Answer:<BR>The historical performance of Brawn Biotech shows a modest financial position as of March 2023, with net sales reported at 0.48 crore and total operating income also at 0.48 crore. The company incurred total expenditure of 0.48 crore, resulting in an operating profit (PBDIT) of 0.24 crore after accounting for other income. The profit before tax stood at 0.22 crore, leading to a profit after tax of 0.19 crore, which translates to a PAT margin of 39.58%. The earnings per share (EPS) were recorded at 0.39, while the diluted EPS was slightly lower at 0.38. <BR><BR>In terms of assets and liabilities, Brawn Biotech's total assets as of March 2023 were 14.37 crore, with total liabilities at 14.37 crore, indicating a balanced sheet with no debt. The company's shareholder's funds were 6.31 crore, and the book value per share adjusted was 21.03. The cash flow results indicate that the company had no cash inflow or outflow from operating, investing, or financing activities, reflecting a stagnant cash position over the years. Overall, Brawn Biotech's financials suggest a company with limited operational activity and a need for growth in revenue generation. <BR><BR>Breakdown:<BR>Brawn Biotech's financial performance as of March 2023 reveals net sales of 0.48 crore, with total operating income matching this figure. The company faced total expenditures of 0.48 crore, leading to an operating profit of 0.24 crore, bolstered by other income. The profit before tax was 0.22 crore, resulting in a profit after tax of 0.19 crore, which corresponds to a PAT margin of 39.58%. The earnings per share were 0.39, while the diluted EPS was slightly lower at 0.38. On the balance sheet, total assets and liabilities were both at 14.37 crore, with shareholder's funds at 6.31 crore and a book value per share of 21.03. The cash flow statements indicate no activity in cash inflows or outflows, suggesting a lack of operational movement in the company's financial activities.

How big is Brawn Biotech?

As of 23rd July, Brawn Biotech Ltd has a market capitalization of 5.00 Cr, with recent net sales of 0.36 Cr and a net profit of 0.21 Cr. Shareholder's funds are 5.07 Cr and total assets amount to 14.13 Cr as of March 2024.

As of 23rd July, Brawn Biotech Ltd has a market capitalization of 5.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Brawn Biotech reported Net Sales of 0.36 Cr and a Net Profit of 0.21 Cr. <BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 5.07 Cr and Total Assets totaling 14.13 Cr.

Who are the peers of the Brawn Biotech?

Brawn Biotech's peers include Unjha Formul., Beryl Drugs, Cian Healthcare, Adline Chem Lab, Ortin Global, Vivanza Biosci., Ganga Pharma., Shyama Computro., and Fabino Enter. Unjha Formul. shows excellent management and the highest 1-year return at 23.34%, while Cian Healthcare has the lowest return at -81.16%.

Peers: The peers of Brawn Biotech are Unjha Formul., Beryl Drugs, Cian Healthcare, Adline Chem Lab, Ortin Global, Vivanza Biosci., Ganga Pharma., Shyama Computro., Fabino Enter.<BR><BR>Quality Snapshot: Excellent management risk is observed at Unjha Formul., while Below Average management risk is found at Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and Fabino Enter, and the rest have management risks that do not qualify. Growth is Below Average for Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and Fabino Enter, while Adline Chem Lab and Shyama Computro. do not qualify for growth. Capital Structure is Good at Unjha Formul., Average at Fabino Enter, and Below Average at Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and the rest.<BR><BR>Return Snapshot: Unjha Formul. has the highest 1-year return at 23.34%, while Cian Healthcare has the lowest at -81.16%, with Brawn Biotech's 1-year return at -19.73% being significantly better than Cian Healthcare's. Additionally, Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and Fabino Enter all have negative six-month returns.

Is Brawn Biotech overvalued or undervalued?

As of June 11, 2024, Brawn Biotech is considered risky and overvalued due to its negative PE ratio of -2.75, poor financial metrics compared to peers, and a year-to-date stock performance decline of -23.04%.

As of 11 June 2024, Brawn Biotech's valuation grade has moved from does not qualify to risky, indicating a significant change in its perceived financial health. The company appears to be overvalued given its negative PE ratio of -2.75, an EV to EBIT of -2.48, and a ROCE of -47.62%. These ratios highlight the company's struggles in generating profits and returns on capital.<BR><BR>In comparison to its peers, Brawn Biotech's financial metrics stand out unfavorably. For instance, MMTC has a PE ratio of 119.39, while PTC India boasts a much more attractive PE of 9.02, showcasing the stark contrast in valuation within the industry. Additionally, Brawn Biotech's recent stock performance has been poor, with a year-to-date return of -23.04% compared to the Sensex's positive return of 5.58%, reinforcing the notion that the company is overvalued in its current state.

What is the technical trend for Brawn Biotech?

As of June 3, 2025, Brawn Biotech's trend has shifted to bearish with moderate strength, driven by daily moving averages and Bollinger Bands, despite mixed signals from the MACD and KST, and a year-to-date return of -19.29% compared to the Sensex's 5.51% gain.

As of 3 June 2025, the technical trend for Brawn Biotech has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the daily moving averages indicating a bearish trend, and both the weekly and monthly Bollinger Bands confirming a bearish outlook. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly, indicating mixed signals. The KST is also mildly bullish weekly but bearish monthly, adding to the overall bearish sentiment. The stock's performance has been weak, with a year-to-date return of -19.29%, contrasting with the Sensex's positive return of 5.51%.

Who are the top shareholders of the Brawn Biotech?

The top shareholders of Brawn Biotech are primarily promoters, with Brij Raj Gupta holding the largest stake at 16.69%. Individual investors own 33.17% of the shares, while the highest public shareholder is Daksha Kotak at 1.24%.

The top shareholders of Brawn Biotech primarily include the promoters, with Brij Raj Gupta holding the largest individual stake at 16.69%. Additionally, individual investors collectively own 33.17% of the shares. The company has no pledged promoter holdings, and there are no foreign institutional investors (FIIs) involved. The highest public shareholder is Daksha Kotak, who holds 1.24%. Overall, the majority of the shares are held by the promoters.

Who are in the management team of Brawn Biotech?

As of March 2021, the management team of Brawn Biotech consists of B R Gupta (Chairman & Managing Director), Brij Bala Gupta (Director), Subhash Chander (Independent Director), Kanta Takkar (Independent Director), and Priyanka Sharma (Company Secretary), all receiving a remuneration of Rs. 0.

As of March 2021, the management team of Brawn Biotech includes:<BR><BR>1. B R Gupta - Chairman & Managing Director<BR>2. Brij Bala Gupta - Director<BR>3. Subhash Chander - Independent Director<BR>4. Kanta Takkar - Independent Director<BR>5. Priyanka Sharma - Company Secretary<BR><BR>All members of the management team have a remuneration of Rs. 0.

Has Brawn Biotech declared dividend?

Brawn Biotech Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 12, 2018. However, the company has shown significant losses over various periods, resulting in a consistent dividend yield of 0% in recent times.

Brawn Biotech Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1<BR>- Ex-date: 12 Sep 18<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -25.42%, the dividend return was 0%, resulting in a total return of -25.42%.<BR><BR>In the 1 year period, the price return was -37.33%, the dividend return was 0%, resulting in a total return of -37.33%.<BR><BR>In the 2 years period, the price return was 1.23%, the dividend return was 0%, resulting in a total return of 1.23%.<BR><BR>In the 3 years period, the price return was -13.68%, the dividend return was 0%, resulting in a total return of -13.68%.<BR><BR>In the 4 years period, the price return was -50.3%, the dividend return was 0%, resulting in a total return of -50.3%.<BR><BR>In the 5 years period, the price return was -40.15%, the dividend return was 0%, resulting in a total return of -40.15%.<BR><BR>Overall, while Brawn Biotech has declared a dividend, the total returns over various periods indicate significant losses, particularly in the longer term, suggesting challenges in the company's financial performance. The consistent dividend yield of 0% in recent periods further reflects a lack of ongoing dividend distributions.